Literature DB >> 34228172

Self-reported late effect symptom clusters among young pediatric cancer survivors.

Rebecca Williamson Lewis1, Karen E Effinger2,3, Karen Wasilewski-Masker2,3, Ann Mertens2,3, Canhua Xiao4.   

Abstract

PURPOSE: Most survivors of childhood cancer experience subsequent chronic conditions but little is known about concurrent symptoms. This study seeks to identify late effect symptom clusters among young pediatric cancer survivors.
METHODS: Survivors ≥ 18 or parents of survivors < 18 years enrolled in an institutional cohort study indicated (yes/no) if they experienced certain symptoms after treatment. The sample was randomly divided in half for exploratory factor analyses to identify symptom clusters followed by confirmatory factor analyses. Symptoms with ≥ 10% prevalence were included. Cluster structure generalizability across subgroups was examined using congruence coefficients.
RESULTS: The sample included 579 survivors (74% non-Hispanic white, 45% leukemia, 12.8 ± 4.5 years at survey, 5.9 ± 3.5 years since therapy). Respondents averaged three symptoms. Three clusters were identified: (1) gastrointestinal: abdominal pain, diarrhea, constipation, nausea, vomiting (Cronbach's α = 0.74); (2) psychological: depression, anxiety, memory problems, anger management problems, sleep problems (α = 0.71); and (3) neurologic: problems walking, numbness/tingling, fatigue, back pain, chronic pain, weakness/inability to move legs (α = 0.71). Confirmatory factor analysis confirmed the three-cluster structure (standardized root mean square residual: 0.09; parsimonious goodness of fit: 0.96; Bentler-Bonett normed fit index: 0.95). The gastrointestinal and psychological clusters were generalizable across most subgroups while the neurologic cluster varied across age and race/ethnicity subgroups.
CONCLUSION: Three distinct late effect symptom clusters were identified in young childhood cancer survivors with gastrointestinal and psychological clusters remaining relatively stable across subgroups. Future studies should focus on the characteristics of patients who experience these symptoms, especially those with high symptom burden, and the synergistic impact on quality of life.

Entities:  

Keywords:  Childhood cancer survivor; Late effects; Pediatric; Symptoms

Year:  2021        PMID: 34228172     DOI: 10.1007/s00520-021-06332-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  33 in total

Review 1.  Symptom clusters: concept analysis and clinical implications for cancer nursing.

Authors:  Hee-Ju Kim; Deborah B McGuire; Lorraine Tulman; Andrea M Barsevick
Journal:  Cancer Nurs       Date:  2005 Jul-Aug       Impact factor: 2.592

2.  Patterns of symptoms and functional impairments in children with cancer.

Authors:  Tyler W Buckner; Jichuan Wang; Darren A DeWalt; Shana Jacobs; Bryce B Reeve; Pamela S Hinds
Journal:  Pediatr Blood Cancer       Date:  2014-03-15       Impact factor: 3.167

3.  Methods for examining cancer symptom clusters over time.

Authors:  Canhua Xiao; Deborah Watkins Bruner; Bonnie Mowinski Jennings; Alexandra L Hanlon
Journal:  Res Nurs Health       Date:  2014-02       Impact factor: 2.228

Review 4.  Advancing the science of symptom management.

Authors:  M Dodd; S Janson; N Facione; J Faucett; E S Froelicher; J Humphreys; K Lee; C Miaskowski; K Puntillo; S Rankin; D Taylor
Journal:  J Adv Nurs       Date:  2001-03       Impact factor: 3.187

5.  Symptom characteristics and clustering in children and adolescents undergoing or being off cancer chemotherapy.

Authors:  S Atay
Journal:  J BUON       Date:  2011 Oct-Dec       Impact factor: 2.533

Review 6.  Consensus Recommendations From the Children's Oncology Group Nursing Discipline's State of the Science Symposium: Symptom Assessment During Childhood Cancer Treatment.

Authors:  Janice S Withycombe; Maureen Haugen; Sue Zupanec; Catherine F Macpherson; Wendy Landier
Journal:  J Pediatr Oncol Nurs       Date:  2019 Jul/Aug       Impact factor: 1.636

7.  Clinical ascertainment of health outcomes among adults treated for childhood cancer.

Authors:  Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

8.  Symptom clustering in older Taiwanese children with cancer.

Authors:  Chao-Hsing Yeh; Yi-Chien Chiang; Lung-Chang Chien; Lin Lin; Chao-Ping Yang; Huo-Li Chuang
Journal:  Oncol Nurs Forum       Date:  2008-03       Impact factor: 2.172

9.  Chronic health conditions in adult survivors of childhood cancer.

Authors:  Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison
Journal:  N Engl J Med       Date:  2006-10-12       Impact factor: 176.079

10.  The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet       Date:  2017-09-08       Impact factor: 79.321

View more
  1 in total

1.  Safety of Complementary and Alternative Medicine (CAM) treatment among children and young adults who suffer from adverse effects of conventional cancer treatment: A systematic review.

Authors:  Dana C Mora; Agnete E Kristoffersen; Grete Overvåg; Miek C Jong; Marit Mentink; Jianping Liu; Trine Stub
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.